Regular use of low-dose aspirin and other anti-inflammatory drugs lowers the risk of certain breast cancers, a new study reports in the journal Breast Cancer Research.

The population-level study is the latest claim touting the long-term use of aspirin in reducing the risk of various cancers.

The low-dose aspirin regimen reduced risk of HR-positive/HER-2 negative breast tumors by 20 percent, the authors conclude.

“Our study strongly supports the need for further, perhaps experimental, study of low-dose aspirin as a widely-available inexpensive chemopreventive option for the most common subtype of breast cancer, the HR-positive/HER2-negative subtype,” the authors write.

The study assessed 57,164 women from the California Teachers Study from 1995 to 2012, following them into retirement and their health practices.

A total of 1,457 of the participants were diagnosed with invasive breast cancer. Based on the self-reported health practices, the part of the group that took low-dose aspirin three times a week or more had the reduced risk of the most common tumor subtype.

It’s not the first indication of the benefits of low-dose aspirin on breast cancer. A meta-analysis in 2008 found the correlation between the mild drug and tumor outcomes within 38 studies and an amalgamation of 2 million women.

The benefits that aspirin and other non-steroidal anti-inflammatory medications (NSAIDs) have on staving off cancer is “not yet clear,” the authors of the latest study write.

“A consistent lowering of COX-2 and prostaglandin activity could prevent or slow carcinogenesis in a number of ways, at the tumor level, by interfering with DNA adduct formation, inhibiting tumor angiogenesis, or promoting apoptosis,” they contend.

Other aspirin-cancer benefits have been found, particularly with digestive tract cancers. A group of studies has found that cancer patients who take more aspirin have been kept alive longer, despite tumors of the esophagus, stomach, colon and rectum.

A recent study by the U.S. Department of Veterans Affairs proposed a theory that aspirin’s effect on platelets causes the inhibitory effects on cancerous cells, as published in February in the journal Cancer Prevention Research. Their theory: that aspirin blocked platelets from assisting tumors in new blood vessel formation, essentially blocking a major pathways of cancer’s spread.